Citation Impact
Citing Papers
Interrater reliability of cardiac output measurements by transcutaneous Doppler ultrasound: implications for noninvasive hemodynamic monitoring in the ED
2006
Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats
1997
Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study
1995
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
1996 Standout
Recent advances: Treatment of myocardial infarction
1998
Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering
2006 Standout
Antithrombotic Therapy for VTE Disease
2016 Standout
Molecular basis of human hypertension: Role of angiotensinogen
1992 Standout
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
Exercise Standards for Testing and Training
2013 Standout
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
2008
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
The renin-angiotensin system in the rat brain
1988
Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions
1995
Initial Results of Reteplase in the Treatment of Acute Lower Extremity Arterial Occlusions
2000
Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and function
1991
Central renin injections: effects on drinking and expression of immediate early genes
1998
Multi-Ethnic Study of Atherosclerosis: Objectives and Design
2002 Standout
Therapeutic potential of β-arrestin- and G protein-biased agonists
2010 StandoutNobel
Cardiac adrenergic receptor effects of carvedilol
1996
Antithrombotic Therapy for VTE Disease
2012 Standout
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Reteplase in the Treatment of Peripheral Arterial and Venous Occlusions: A Pilot Study
2000
cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action
2010 Standout
Biomedical applications of bisphosphonates
2013
Growth Factor Delivery for Bone Tissue Engineering
2001
Inability of [125I]Sar1, Ile8‐Angiotensin II to Move Between the Blood and Cerebrospinal Fluid Compartments
1988
Cardiorenal Syndrome
2008 Standout
Effect of Carvedilol on Survival in Severe Chronic Heart Failure
2001 Standout
Generation and application of new rat monoclonal antibodies against synthetic FLAG and OLLAS tags for improved immunodetection
2007 StandoutNobel
The Management of Chronic Heart Failure
1996
Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism
1999
Pharmacology of carvedilol
2004
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
2009 Standout
Renin-1 Is Essential for Normal Renal Juxtaglomerular Cell Granulation and Macula Densa Morphology
1997
Physiology of Local Renin-Angiotensin Systems
2006 Standout
Importance of quantitative genetic variations in the etiology of hypertension
2000 StandoutNobel
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
1997 Standout
A review on emerging contaminants in wastewaters and the environment: Current knowledge, understudied areas and recommendations for future monitoring
2014 Standout
Important roles for angiotensin III and IV in the brain renin-angiotensin system
1997
Bisphosphonates: The first 40years
2011
Perioperative fluid management in renal transplantation: a narrative review of the literature
2006
Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents
1993
The pharmacology of carvedilol
1990
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
1999 Standout
Homeostasis in Mice with Genetically Decreased Angiotensinogen Is Primarily by an Increased Number of Renin-producing Cells
1999 StandoutNobel
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
Pressor and Renal Effects of Intracerebroventricularly Administered Angiotensins II and III in Rats
2000
Tissue Plasminogen Activator in Cardiac Arrest with Pulseless Electrical Activity
2002
Naturally occurring p16Ink4a-positive cells shorten healthy lifespan
2016 StandoutNature
The Neuroendocrinology of Thirst and Salt Appetite: Visceral Sensory Signals and Mechanisms of Central Integration
1997
Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research
2001
Molecular evidence of tissue renin-angiotensin systems: A focus on the brain
2005
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study
2001
Antithrombotic Therapy for Venous Thromboembolic Disease
2004 Standout
Regulatory role of brain angiotensins in the control of physiological and behavioral responses
1992
Bisphosphonate conjugation for bone specific drug targeting
2018
Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene
1990 Nature
Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling
2000 Standout
Human genetics, animal models and computer simulations for studying hypertension☆
2004 StandoutNobel
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs
2011
The classification of prostaglandin DP‐receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist
1989
Brain Renin-Angiotensin System
2003
Targeted delivery to bone and mineral deposits using bisphosphonate ligands
2015
Engineering proteins to facilitate bioprocessing
1994
High blood pressure in transgenic mice carrying the rat angiotensinogen gene.
1992
Double-Blind, Placebo-Controlled Study of the Long-term Efficacy of Carvedilol in Patients With Severe Chronic Heart Failure
1995
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
2005 Standout
Angiotensin levels in the eye.
1994
Prostanoid Receptors: Structures, Properties, and Functions
1999 Standout
Genetic Models of Human Vascular Disease
1995 StandoutNobel
Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)
2013 Standout
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
2006 Standout
Prospective Study of Heart Rate Variability and Mortality in Chronic Heart Failure
1998 Standout
International Union of Pharmacology. XXIII. The Angiotensin II Receptors
2000 Standout
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Angiotensin degradation products mediate endothelium-dependent dilation of rabbit brain arterioles.
1991
Single-nanometer iron oxide nanoparticles as tissue-permeable MRI contrast agents
2021 StandoutNobel
A genetically clamped renin transgene for the induction of hypertension
2002 StandoutNobel
A Comparison of Reteplase with Alteplase for Acute Myocardial Infarction
1997
A Noninvasive Computerized Tail-Cuff System for Measuring Blood Pressure in Mice
1995 StandoutNobel
In Vitro and In Vivo Characterization of Intrinsic Sympathomimetic Activity in Normal and Heart Failure Rats
1999
Presence of angiotensin II in neurons cultured from fetal rat brain
1980
Reciprocal In Vivo Regulation of Myocardial G Protein–Coupled Receptor Kinase Expression by β-Adrenergic Receptor Stimulation and Blockade
1998 StandoutNobel
Gene Targeting Approaches to Analyzing Hypertension
1999 StandoutNobel
International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes.
1994 Standout
Genetic control of blood pressure and the angiotensinogen locus.
1995 StandoutNobel
A micromethod for the measurement of renin in brain nuclei: Its application in spontaneously hypertensive rats
1982
Beneficial Effects of Intravenous and Oral Carvedilol Treatment in Acute Myocardial Infarction
1997
Identity of angiotensinogen precursors of rat brain and liver
1984 Nature
The Oxytocin Receptor System: Structure, Function, and Regulation
2001 Standout
Intrathecally administered angiotensin II increases sympathetic activity in the rat
1987
Thrombolytic Treatment with Tissue-type Plasminogen Activator (t-PA) Containing Liposomes in Rabbits: a Comparison with Free t-PA
1995
Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism
2013 Standout
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Targeted Inactivation of the Ren-2 Gene in Mice
1996
Characterization of prostanoid relaxant/inhibitory receptors (ψ) using a highly selective agonist, TR4979
1986
Effects of central infusion of ANG II and losartan on the cardiac baroreflex in rabbits
2000
Part 8: Adult Advanced Cardiovascular Life Support
2010 Standout
Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.
2001
Molecular phenotyping for analyzing subtle genetic effects in mice: Application to an angiotensinogen gene titration
2002 StandoutNobel
Works of G. Sponer being referenced
Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis
1992
Prevention of Cold-Preservation Injury of CulturedEndothelial Cells by Catecholamines and Related Compounds
2003
Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro
1993
New model for simulation of fracture repair in full-grown beagle dogs: Model characterization and results from a long-term study with ibandronate
2004
Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli
1992
Pharmacological characteristics of the stereoisomers of carvedilol
1990
Haemodynamic profile of an inhibitor of phosphodiesterase III, adibendan (BM 14.478): comparison with nitroprusside and dobutamine in conscious dogs
1990
Effect of 17β-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17β-estradiol serum kinetics and bone mass in rats
1996
Rapid Reversal of Canine Thromboembolic Pulmonary Hypertension by Bolus Injection of the Novel Recombinant Plasminogen Activator BM 06.022
1993
Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
1984
Studies on the Mode of Vasodilating Action of Carvedilol
1987
Pharmacokinetics of the novel recombinant plasminogen activator BM 06.022 in rats, dogs, and non-human primates
1992
BM 06.022: A Novel Recombinant Plasminogen Activator
1993
Studies on the Mode of Vasodilating Action of Carvedilol*
1987
Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule.
1990
Components of the Renin-Angiotensin System in the Cerebrospinal Fluid of Rats and Dogs with Special Consideration of the Origin and the Fate of Angiotensin II
1980
Pharmacological Profile of Carvedilol, a Compound with β-Blocking and Vasodilating Properties
1987
Impermeability of the Blood—Cerebrospinal Fluid Barrier for Angiotensin II in Rats
1976
Pharmacological Profile of Carvedilol as a β-Blocking Agent with Vasodilating and Hypotensive Properties
1987